Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-03-22
2011-03-22
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C514S012200
Reexamination Certificate
active
07910105
ABSTRACT:
The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).
REFERENCES:
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5665772 (1997-09-01), Cottens et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6258562 (2001-07-01), Salfeld et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6350892 (2002-02-01), Banville et al.
patent: 6576744 (2003-06-01), Presnell et al.
patent: 6777539 (2004-08-01), Sprecher et al.
patent: 6929932 (2005-08-01), Presnell et al.
patent: 7189400 (2007-03-01), Carter et al.
patent: 7198789 (2007-04-01), Carter et al.
patent: 7276478 (2007-10-01), Sivakumar et al.
patent: 7314623 (2008-01-01), Grusby et al.
patent: 7495085 (2009-02-01), Valge-Archer et al.
patent: 2003/0118592 (2003-06-01), Ledbetter et al.
patent: 2003/0133939 (2003-07-01), Ledbetter et al.
patent: 2004/0009150 (2004-01-01), Nelson et al.
patent: 2004/0016010 (2004-01-01), Kasaian et al.
patent: 2004/0058445 (2004-03-01), Ledbetter et al.
patent: 2005/0136049 (2005-06-01), Ledbetter et al.
patent: 2005/0175614 (2005-08-01), Ledbetter et al.
patent: 2005/0180970 (2005-08-01), Ledbetter et al.
patent: 2005/0186216 (2005-08-01), Ledbetter et al.
patent: 2005/0202012 (2005-09-01), Ledbetter et al.
patent: 2005/0202023 (2005-09-01), Ledbetter et al.
patent: 2005/0202028 (2005-09-01), Ledbetter et al.
patent: 2005/0202534 (2005-09-01), Ledbetter et al.
patent: 2005/0238646 (2005-10-01), Ledbetter et al.
patent: 2006/0024268 (2006-02-01), Kasaian et al.
patent: 2006/0039902 (2006-02-01), Young et al.
patent: 2006/0159655 (2006-07-01), Collins et al.
patent: 2008/0167241 (2008-07-01), Donaldson et al.
patent: 2008/0241098 (2008-10-01), Young et al.
patent: 2009/0197803 (2009-08-01), Grusby et al.
patent: WO 99/47675 (1999-09-01), None
patent: WO 00/53761 (2000-09-01), None
patent: WO 00/56772 (2000-09-01), None
patent: WO 01/55112 (2001-08-01), None
patent: WO 01/85792 (2001-11-01), None
patent: WO 03/028630 (2003-04-01), None
patent: WO 03/087320 (2003-10-01), None
patent: WO 2004/007682 (2004-01-01), None
patent: WO 2004/083249 (2004-09-01), None
patent: WO2004083249 (2004-09-01), None
patent: WO 2004/084835 (2004-10-01), None
patent: WO 2005/030196 (2005-04-01), None
patent: WO 2005/112983 (2005-12-01), None
patent: WO 2006/135385 (2006-12-01), None
patent: WO 2009/100035 (2009-08-01), None
Elliot Marshall, Science, Mar. 2006, vol. 311, pp. 1688-1689.
Alfarano et al. (2005) “The Biomolecular Interaction Network Database and related tools 2005 update”Nuc. Acids Res. Database Issue33:D418-24.
Bonecchi et al. (1998) “Divergent Effects of Interleukin-4 and Interferon-γ on Macrophage-Derived Chemokine Production: An Amplification Circuit of Polarized T Helper 2 Responses”Blood92:2668-71.
Chiaramonte et al. (1999) “An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2—dominated inflammatory response”J. Clin. Invest.104:777-85.
Chiaramonte et al. (2003) “Regulation and Function of the Interleukin 13 Receptor α 2 During a T Helper Cell Type 2—dominant Immune Response”J. Exp. Med.197:687-701.
Collins et al. (2003) “IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity”Immunol. Res.28:131-40.
Distler et al. (2005) “Expression of Interleukin-21 Receptor in Epidermis from Patients with Systemic Sclerosis” Arthirtis Rheum. 52:856-64.
Davis et al. (2005) “Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase”Proc. Natl. Acad. Sci. USA102:5981-86.
Di Carlo et al. (2004) “IL-21 Induces Tumor Rejection by Specific CTL and IFN-γ-Dependent CXC Chemokines in Syngeneic Mice”J. lmmunol.172:1540-47.
Elit (2002) “CCI-779 Wyeth”Curr. Opin. Investig. Drugs3(8):1249-53.
Fallon et al. (2000) “Schistosome Infection of Transgenic Mice Defines Distinct and Contrasting Pathogenic Roles for IL-4 and IL-13: IL-13 Is a Profibrotic Agent”J. Immunol.164:2585-91.
Fichtner-Feigl et al. (2006) “IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-beta1 production and fibrosis”Nat. Med.12:99-106.
Gordon (2003) “Alternative activation of macrophages”Nat. Rev. Immunol.3:23-35.
Guo et al. (2000) “Biochemical Characterization of Endogenously Formed Eosinophilic Crystals in the Lungs of Mice”J. Biol. Chem.275:8032-37.
Habib et al. (2003) “IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses”J. Allergy Clin. Immunol.112:1033-45.
Halpin and Harbury (2004) “DNA Display II. Genetic Manipulation of Combinatorial Chemistry Libraries for Small-Molecule Evolution”PLoS Biology2:1022-30.
Herbert et al. (2004) “Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology”Immunity20:623-35.
Hesse et al. (2000) “NOS-2 Mediates the Protective Anti-Inflammatory and Antifibrotic Effects of the Th1-Inducing Adjuvant, IL-12, in a Th2 Model of Granulomatous Disease”Am. J. Pathol.157:945-55.
Hesse et al. (2001) “Differential Regulation of Nitric Oxide Synthase-2 and Arginase-1 by Type 1/Type 2 Cytokines In Vivo: Granulomatous Pathology Is Shaped by the Pattern of L-Arginine Metabolism”J. Immunol.167:6533-44.
Hoffmann et al. (1999) “Studies with Double Cytokine-Deficient Mice Reveal That Highly Polarized Th1- and Th2-Type Cytokine and Antibody Responses Contribute Equally to Vaccine-Induced Immunity toSchistosoma mansoni” J. lmmunol.163:927-938.
Hoffmann et al. (2000) “IL-10 and the Dangers of Immune Polarization: Excessive Type 1 and Type 2 Cytokine Responses Induce Distinct Forms of Lethal Immunopathology in Murine Schistosomiasis”J. Immunol.164:6406-16.
Huang and Houghton (2002) “Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic”Curr. Opin. Investig. Drugs3:295-304.
Jakubzick et al. (2003) “Impact of Interleukin-13 Responsiveness on the Synthetic and Proliferative Properties of Th1- and Th2-Type Pulmonary Granuloma Fibroblasts”Am. J. Pathol.162:1475-86.
Jankovic et al. (1999) “Schistosome-Infected IL-4 Receptor Knockout (KO) Mice, in Contrast to IL-4 KO Mice, Fail to Develop Granulomatous Pathology While Maintaining the Same Lymphokine Expression Profile”J. Immunol.163:337-42.
Jin et al. (2004) “Distinct Activation Signals Determine Whether IL-21 Induces B Cell Costimulation, Growth Arrest, or Bim-Dependent Apoptosis”J. Immunol.173:657-65.
Kaplan et al. (1998) “Th2 Cells Are Required for theSchistosoma mansoniEgg-Induced Granulomatous Response”J. Immunol.160:1850-56.
Karp (2000) “An ontology for biological function based on molecular interactions”Bioin
Collins Mary
Grusby Michael J.
Wynn Thomas A.
Young Deborah A.
Bunner Bridget E
Fitzpatrick ,Cella, Harper & Scinto
Hamud Fozia M
President and Fellows of Harvard College
The United States of America as represented by the Department of
LandOfFree
Methods for treating and preventing fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating and preventing fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating and preventing fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2737122